Key result
ACE insertion/deletion genotype linked to ~2.1-fold higher odds of multimorbidity vs deletion/deletion genotype.
Why the study?
The study assessed whether the angiotensin-converting enzyme insertion/deletion polymorphism is associated with accumulation of cardiometabolic and endocrine conditions in adults.
Does the ACE insertion/deletion polymorphism associate with higher odds of cardiometabolic and endocrine multimorbidity in community-recruited adults?
Cross-Sectional (n=544)
Yes
Does the ACE insertion/deletion polymorphism associate with higher odds of cardiometabolic and endocrine multimorbidity in community-recruited adults?
Odds Ratio: 2.15 (95% CI 1.19–3.9)
p-value: p=0.011
The ACE insertion/deletion (ID) genotype is associated with a significantly increased risk of cardiometabolic and endocrine multimorbidity compared to the DD genotype in an Algerian cohort.
The accumulation of chronic conditions may reflect shared biological susceptibility. We assessed whether the angiotensin-converting enzyme insertion/deletion polymorphism was associated with four prespecified, participantreported, physician-diagnosed conditions. This multisite cross-sectional study included 544 adults consecutively recruited from community settings across eight wilayas in Eastern Algeria. Multimorbidity was defined as at least two of the following conditions: hypertension, diabetes, thyroid dysfunction, and cardiac disease. Logistic regression was adjusted for age, sex, and tobacco use. Among the 544 participants, 84 (15.4%) had multimorbidity. Genotype was a significant contributor to the adjusted model (likelihood-ratio P=0.037). Compared with the deletion/deletion (DD) genotype, the insertion/deletion (ID) genotype was associated with higher odds of multimorbidity (adjusted odds ratio, 2.15; 95% confidence interval, 1.19-3.90; P=0.011), whereas the estimate for the insertion/insertion (II) genotype was imprecise and not statistically significant (adjusted odds ratio, 0.74; 95% confidence interval, 0.20-2.77; P=0.656). The ID genotype was associated with the presence of at least two conditions but not with exactly one condition, and no additive association with the D allele was detected. Genotype frequencies deviated from Hardy–Weinberg equilibrium (exact P=2.53 × 10⁻⁷ ), reflecting a heterozygote deficit. Bias analysis indicated that non-differential misclassification of heterozygotes as DD would attenuate the observed association. These findings suggest an association between the ID genotype and multimorbidity, although they should be interpreted cautiously and confirmed in independent studies.
No takes yet. Share an insight, caveat, or question.
Meroua et al. (2026) conducted a cross-sectional in Multimorbidity (n=544). Angiotensin-converting enzyme insertion/deletion (ID) genotype vs. Deletion/deletion (DD) genotype was evaluated on Multimorbidity (at least two of: hypertension, diabetes, thyroid dysfunction, and cardiac disease) (adjusted OR 2.15, 95% CI 1.19-3.90, p=0.011). The ACE insertion/deletion genotype was associated with significantly higher odds of multimorbidity compared to the deletion/deletion genotype (adjusted OR 2.15; 95% CI 1.19-3.90; P=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: